Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 4, 2004. The report details a share repurchase transaction executed on November 3, 2004, and updates regarding Directors' interests in Ordinary Share ADRs as of November 4, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback and dividend reinvestment:
- Share Repurchase Price: 1,185.33 pence per share.
- Dividend Reinvestment Price: $43.73 per share (for ADRs).
Material Changes
The primary material change reported is the reduction of outstanding shares due to a treasury stock purchase:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Treasury Holdings: Following the purchase, the Company holds 49,978,000 shares in Treasury.
- Shares in Issue: 5,885,998,623 shares (excluding Treasury shares).
- Directors' Interests: Increases in holdings for Dr. J P Garnier (310 ADRs), Dr. T Yamada (200 ADRs), and S M Bicknell (Company Secretary) occurred due to dividend reinvestment under the Executive Supplemental Savings Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (49,978,000) against subsequent filings to track buyback progress.
- Confirm the total number of shares in issue (5,885,998,623) for accurate earnings-per-share calculations.
- Review the Annual General Meeting minutes from May 17, 2004, to confirm the scope of the share repurchase authority utilized.
- Check the specific terms of the Executive Supplemental Savings Plan regarding dividend reinvestment rates.